Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HFB3-1
- Development stage
- Unknown
- Lead developer
- HiFiBiO Therapeutics
01
Overview
HFB3-1: sourced facts only. name: "We investigated the pharmacokinetic (PK), pharmacodynamics (PD), and anti-tumor efficacy of an anti-TNFR2 agonist, HFB3-1, and an anti-OX40 agonist, HFB10-1, in syngeneic tumor models." [DOI:10.1158/1538-7445.am2024-7176]; target: "We investigated the pharmacokinetic (PK), pharmacodynamics (PD), and anti-tumor efficacy of an anti-TNFR2 agonist, HFB3-1, and an anti-OX40 agonist, HFB10-1, in syngeneic tumor models." [DOI:10.1158/1538-7445.am2024-7176]; developer: "1HiFiBiO Therapeutics, Cambridge, MA." [DOI:10.1158/1538-7445.am2024-7176]; stage: "We investigated the pharmacokinetic (PK), pharmacodynamics (PD), and anti-tumor efficacy of an anti-TNFR2 agonist, HFB3-1, and an anti-OX40 agonist, HFB10-1, in syngeneic tumor models." [DOI:10.1158/1538-7445.am2024-7176]
02
Targets
TNFR2 (Tumor necrosis factor receptor superfamily member 1B)
Beyond the preview
Go deeper on HFB3-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HFB3-1.